This inventor holds 1 USPTO granted patent. Top assignee: Daiichi Sankyo Company, Limited. Active years: 2015.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015
Title: Innovator Spotlight: Kathrin Ladetzki Baehs and Her Groundbreaking Work on Antibodies
Introduction: Kathrin Ladetzki Baehs is a prominent inventor based in Martinsried/Planegg, Germany. With a strong focus on therapeutic innovations, she has made significant contributions to the field of biotechnology. Her work primarily revolves around antibodies, which play a crucial role in treating various diseases by targeting specific proteins involved in cellular processes.
Latest Patents: Kathrin holds a patent for an antibody targeting the osteoclast-related protein Siglec-15. This innovative antibody is designed to inhibit osteoclast formation and/or osteoclastic bone resorption. The technical details of her patent are impressive: it includes a heavy chain with unique complementarity-determining regions (CDRs) and a light chain that also comprises specific CDR sequences, ensuring precise binding and functionality.
Career Highlights: Throughout her career, Kathrin has been dedicated to advancing the field of immunology and therapeutic development. Her work at Daiichi Sankyo Company, Limited, has allowed her to contribute to the development of new treatments that leverage the power of antibodies. With her expertise, she has played a vital role in translating research breakthroughs into potential therapeutic applications.
Collaborations: Collaborating with esteemed colleagues such as Ichiro Watanabe and Yoshiharu Hiruma, Kathrin has been part of a team that fosters innovation and drives research forward. These partnerships highlight the importance of teamwork in the scientific community and how collaborative efforts can lead to impactful discoveries.
Conclusion: Kathrin Ladetzki Baehs exemplifies the spirit of innovation in the field of biotechnology. Her patent on an antibody targeting Siglec-15 is a testament to her dedication and expertise. As she continues her work at Daiichi Sankyo Company, Limited, Kathrin remains a key figure in the ongoing quest to harness the power of antibodies in therapeutic settings, paving the way for future advancements in medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile